首页> 外文期刊>Ultrastructural pathology >Type 1 protein tyrosine kinases in breast carcinoma: a review.
【24h】

Type 1 protein tyrosine kinases in breast carcinoma: a review.

机译:乳腺癌中的1型蛋白酪氨酸激酶:综述。

获取原文
获取原文并翻译 | 示例
           

摘要

One of the most studied onco-gene families in breast tumors is the type 1 protein tyrosine kinase family, which consists of EGFR, c-erbB-2, c-erbB-3, and c-erbB-4. Overexpression of c-erbB-2 protein/mRNA in breast carcinomas is consistently associated with poor prognosis, while EGFR overexpression has been confirmed to have a synergistic clinical effect on the c-erbB-2 influence. The expression pattern of c-erbB-4 in breast carcinomas is special. Unlike other type 1 protein tyrosine kinases, expression of c-erbB-4 protein/mRNA is reduced in carcinomas compared with that in normal breast epithelia, and its expression has also been associated with a better clinical outcome, indicating the need for c-erbB-4 analysis when clinical therapeutic application of EGFR and c-erbB-2 anitbodies is considered. In addition, studies of the adaptor proteins in breast carcinomas are highly indicated in order to clarify the mechanisms behind the dysregulated expression of such receptors in breast carcinomas.
机译:乳腺癌中研究最多的癌基因家族之一是1型蛋白酪氨酸激酶家族,该家族由EGFR,c-erbB-2,c-erbB-3和c-erbB-4组成。乳腺癌中c-erbB-2蛋白/ mRNA的过表达始终与不良预后相关,而EGFR过表达已被证实对c-erbB-2的影响具有协同临床作用。 c-erbB-4在乳腺癌中的表达模式是特殊的。与其他1型蛋白酪氨酸激酶不同,与正常乳腺上皮相比,c-erbB-4蛋白/ mRNA在癌症中的表达降低,并且其表达也与更好的临床结局相关,表明需要c-erbB -4分析考虑了EGFR和c-erbB-2抗体的临床治疗应用时。另外,高度阐明了在乳腺癌中对衔接子蛋白的研究,以阐明乳腺癌中这种受体表达失调的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号